Department of Biology, University of Ottawa, Ottawa, Ontario, Canada.
Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada.
Environ Mol Mutagen. 2024 Oct;65(8):234-242. doi: 10.1002/em.22619. Epub 2024 Sep 12.
Regulatory genetic toxicology testing is essential for identifying potentially mutagenic hazards. Duplex Sequencing (DS) is an error-corrected next-generation sequencing technology that provides substantial advantages for mutation analysis over conventional mutagenicity assays including: improved accuracy of mutation detection, ability to measure changes in mutation spectrum, and applicability across diverse biological models. To apply DS for regulatory toxicology testing, power analyses are required to determine suitable sample sizes and study designs. In this study, we explored study designs to achieve sufficient power for various effect sizes in chemical mutagenicity assessment. We collected data from MutaMouse bone marrow and liver samples that were analyzed by DS using TwinStrand's Mouse Mutagenesis Panel. Average duplex reads achieved in two separates studies on liver and bone marrow were 8.4 × 10 (± 7.4 × 10) and 9.5 × 10 (± 1.0 × 10), respectively. Baseline mean mutation frequencies (MF) were 4.6 × 10 (± 6.7 × 10) and 4.6 × 10 (± 1.1 × 10), with estimated standard deviations for the animal-to-animal random effect of 0.15 and 0.20, for liver and bone marrow, respectively. We conducted simulation analyses based on these empirically derived parameters. We found that a sample size of four animals per group is sufficient to obtain over 80% power to detect a two-fold change in MF relative to baseline. In addition, we estimated the minimal total number of informative duplex bases sequenced with different sample sizes required to retain power for various effect sizes. Our work provides foundational data for establishing suitable study designs for mutagenicity testing using DS.
监管遗传毒理学测试对于识别潜在的致突变危害至关重要。双串联测序(DS)是一种经过纠错的下一代测序技术,与传统的致突变性检测相比,它在突变分析方面具有显著优势,包括:提高突变检测的准确性、能够测量突变谱的变化,以及适用于各种生物模型。为了将 DS 应用于监管毒理学测试,需要进行功效分析以确定合适的样本量和研究设计。在这项研究中,我们探讨了研究设计,以实现化学致突变性评估中各种效应大小的足够功效。我们收集了来自 MutaMouse 骨髓和肝脏样本的数据,这些数据通过 TwinStrand 的 Mouse Mutagenesis Panel 进行了 DS 分析。在两个单独的肝脏和骨髓研究中,平均双串联读取数分别为 8.4×10(±7.4×10)和 9.5×10(±1.0×10)。基线平均突变频率(MF)分别为 4.6×10(±6.7×10)和 4.6×10(±1.1×10),动物间随机效应的估计标准差分别为 0.15 和 0.20,分别用于肝脏和骨髓。我们根据这些经验得出的参数进行了模拟分析。我们发现,每组四个动物的样本量足以获得超过 80%的功效,以检测相对于基线的 MF 两倍变化。此外,我们还估计了在不同样本量下需要测序的最小信息量双串联碱基数量,以保留各种效应大小的功效。我们的工作为使用 DS 进行致突变性测试建立合适的研究设计提供了基础数据。